Madison Vaccines Announces Patient Dosing Underway in Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, Mvi-816, with Pd1 Inhibitor Pembrolizumab|
Madison Vaccines Incorporated announced dosing has begun in a combination trial for MVI-816 (pTVG-HP), its lead prostate cancer vaccine, paired with pembrolizumab (Keytruda®), a PD-1 inhibitor, also called a checkpoint inhibitor. [Madison Vaccines Incorporated] Press Release
$120,000 in Cancer Research Pilot Grants Awarded to Promote Collaboration
The University of Cincinnati Cancer Institute has awarded four $40,000 research pilot grants to aid in the interaction and collaboration between basic scientific and clinical investigators and facilitate the translation of laboratory findings into clinical therapies. [University of Cincinnati] Press Release
$52 Million NIH Grant Advances Clinical and Translational Research at UC San Diego
The Clinical and Translational Research Institute at University of California, San Diego has received a five-year Clinical and Translational Science Award for approximately $52 million from the National Center for Advancing Translational Science, part of the National Institutes of Health (NIH). [UC San Diego Health] Press Release
From our sponsor:
Want to learn more about ALDH in breast cancer treatment response? Listen to the podcast.